Quantum announces a drug discovery collaboration with Tibotec Pharmaceuticals (subsidiary of Johnson & Johnson).
Under the terms of the agreement Quantum will provide Tibotec Pharmaceuticals with the family of anti-viral drug hits. The drug hits were discovered by Quantum using its proprietary discovery technology. Tibotec Pharmaceuticals is to further evaluate and develop transferred molecules. Financial terms of the collaboration were not disclosed.
About Tibotec Pharmaceuticals BVBA
Tibotec BVBA is a global pharmaceutical and research development company. The Company’s main research and development facilities are in Mechelen, Belgium with offices in Yardley, Pa. and Cork, Ireland. Tibotec is dedicated to the discovery and development of innovative HIV/AIDS and hepatitis C drugs, and anti-infectives for diseases of high unmet medical need.
About Quantum
Quantum is a drug discovery company based in Moscow, Russia specializing in small molecule screening and design through the use of its proprietary technology platform.
More From fedichev
- Quantum Pharmaceuticals and Otechestvennye Lekarstva OJSC entered drug discovery collaboration.
- Quantum Pharmaceuticals and Institute of Pulmonology entered COPD drug discovery collaboration.
- Quantum Pharmaceuticals collaborates with Fox Chase Cancer Center on discovery of new small molecules inhibitors in cancer area.
Related posts:
- HIV-1 integrase drug discovery collaboration
- Quantum and Institute of Pulmonology entered COPD drug discovery collaboration.
- Quantum and Otechestvennye Lekarstva OJSC entered drug discovery collaboration.
- Quantum collaborates with Fox Chase Cancer Center on discovery of new small molecules inhibitors in cancer area.
- Quantum collaborates with University of Pittsburgh on HIV drug discovery.
